Pericarditis may be a serious complication of malignancy. Its significance as a first symptom of occult cancer and as a prognostic factor for cancer survival is unknown.
P
ericarditis, the most common disease of the pericardium, is a relatively benign and self-limiting disease, 1 with an annual incidence rate of ≈30 per 100 000 people. 2 Although its pathogenesis remains elusive in many patients, up to two thirds of the cases are attributable to infection, predominantly with viral pathogens. 3, 4 Other known risk factors are recent cardiothoracic surgery, recent myocardial infarction, recent bacterial infection, autoimmune disease, and cancer. 4, 5 In unselected cohorts of patients with pericarditis, ≈5% of cases are attributed to cancer pathogenesis. 4, 6, 7 However, in patients with pericarditis and pericardial effusion, malignancy is more prevalent, ranging between 12% and 23%. [8] [9] [10] [11] Cancer-related pericarditis may develop via direct infiltration by malignant cancer cells from adjacent structures, pericardial hemorrhage, or hematogenous dissemination of cancer cells. 12 In addition, pericarditis may occur as part of the paraneoplastic syndrome. 13 Among patients with acute pericarditis or pericardial effusions, cancers of the lung and breast and hematologic malignancies are diagnosed most frequently. [14] [15] [16] Case reports describe pericarditis as an early manifestation of lymphoma, gastric cancer, or ovarian cancer. [17] [18] [19] [20] However, the magnitude of cancer risk in patients with pericarditis remains unknown.
In this Danish cohort study, we examined the risk of subsequent cancer among patients with a first-time diagnosis of pericarditis with or without pericardial effusion compared with the general population. Because pericarditis may predict an advanced cancer stage, it may also predict poorer cancer survival. We investigated this hypothesis by comparing survival in matched cohorts of cancer patients with and without pericarditis.
METHODS

Study Design and Setting
This cohort study was based on the cumulative source population of 7 107 948 individuals in Denmark between 1994 and 2013. The Danish healthcare system provides tax-supported medical care to all Danish residents, including access to hospitals and outpatient clinics. 21 In the present study, we used data from the Danish National Patient Registry, 22 in which diagnoses are coded according to the International Classification of Diseases, Eighth Revision and 10th Revision. In the Danish National Patient Registry, the main condition prompting a hospital contact is recorded in the primary diagnosis field, and other relevant diagnoses are recorded in secondary diagnosis fields.
We obtained information on cancer from the Danish Cancer Registry (DCR), which has recorded incident primary cancers in Denmark since 1943, 23 classified according to the International Classification of Diseases-10th Revision. The DCR is virtually complete, and its diagnoses are highly valid. 24 Information on mortality was derived from the Danish Civil Registration System, which has monitored changes in vital status and migration on a daily basis for the entire Danish population since 1968.
Patients With Acute Pericarditis
We identified all patients (hospital inpatients, hospital outpatients, and emergency room patients) with a primary or secondary diagnosis of acute pericarditis (including unspecified pericarditis, infectious pericarditis, pericardial effusion, and pericarditis with underlying autoimmune disease) using International Classification of Diseases-10th Revision diagnosis codes between January 1, 1994, and November 30, 2013. We excluded patients diagnosed with pericarditis recorded before 1994.
We retrieved information from the Danish National Patient Registry starting in 1977 on comorbidities, including tuberculosis, connective tissue disease, and chronic obstructive pulmonary disease as a proxy for heavy smoking. We also obtained information on the following diagnoses registered during or within 30 days before the hospital contact for pericarditis: cardiothoracic surgery, cardiac catheterization, pneumonia/empyema, sepsis, and acute myocardial infarction. We documented the number of patients who underwent echocardiography or other relevant imaging of the chest in connection with their hospital contact for pericarditis (within 30 days before or after this contact).
Cancer Outcomes
We linked data from the members of the pericarditis cohort to the DCR to identify previous and subsequent cancer diagnoses (other than nonmelanoma skin cancer) and restricted the pericarditis cohort to patients without a previous cancer diagnosis.
Clinical Perspective
What Is New?
• Patients with newly diagnosed pericarditis had higher risks than age-and sex-matched members of the general population of being diagnosed with lung cancer, non-Hodgkin lymphoma, and myeloid leukemia during the first 3 months after a pericarditis diagnosis.
• The increased risk for lung cancer, non-Hodgkin lymphoma, and bladder cancer persisted beyond 1 year after a pericarditis diagnosis.
• The increased cancer risk was not restricted to patients with pericardial effusion.
• Pericarditis was a prognostic factor for survival after lung cancer, breast, and bladder cancer.
What Are the Clinical Implications?
• Patients with pericarditis, particularly when complicated by pericardial effusion, may need to be considered for workup targeted at diagnosing or ruling out cancer.
For the analysis of cancer survival, we selected all patients in the pericarditis cohort who subsequently developed cancer and matched them to up to 5 cancer patients identified in DCR without a pericarditis diagnosis preceding cancer diagnosis by sex, age (5-year intervals), year of pericarditis diagnosis (5-year intervals), and cancer site. For the most frequent cancer types (non-Hodgkin lymphoma, lung, breast, bladder, colon, and prostate cancer), we also matched by cancer stage (Ann Arbor staging for non-Hodgkin lymphoma, and tumor/ node/metastasis staging for other cancers) and repeated the cancer-specific analysis.
Statistical Analysis
Each patient with pericarditis was followed up for cancer occurrence from the date of the first hospital contact with a discharge diagnosis of pericarditis until the date of death, date of emigration, or November 30, 2013, whichever came first. The cumulative incidence (or risk) of cancer in patients with pericarditis was computed with death (without cancer) treated as a competing risk. 25 We tested equality of the cumulative incidence functions by sex, age group, pericarditis type, type of hospitalization, and type of diagnosis using Gray 26 tests. We used indirect standardized incidence ratios (SIRs) as a measure of relative risk, comparing the cancer incidence observed among patients with pericarditis with that expected in the general Danish population (The observed number of a specific cancer subtype was compared with the expected number of that specific subtype). 27 We computed the expected numbers of cancer cases on the basis of national cancer incidence rates by age (±1 year), sex, and the calendar year (±1 year) of the pericarditis diagnosis. Using the Byar approximation, 28 we computed 95% confidence intervals (CIs) for the SIRs on the basis of the assumption that the observed number of cases followed a Poisson distribution. SIRs were computed for all cancers combined and for each cancer type separately. We split the follow-up time into 3 periods: <3, 3 to <12 months, and ≥12 months, determined a priori. The aim was detecting occurrence of occult cancer related to the acute event (ie, <3 months), long-term cancer risk (ie, ≥12 months), and any potential compensatory deficit indicating detection bias (ie, 3-<12 months). We used a single Cox model to obtain the estimates for the various time intervals using an interaction between time interval and exposure. We stratified our analyses by sex, age group (<30, 30-49, 50-69, ≥70 years), primary versus secondary diagnosis, type of pericarditis, and the covariates. In a post hoc analysis prompted by large differences in risk by pericardial effusion status in our main set of stratified analyses, we computed SIRs for all cancer types and by time period for patients with pericardial effusion and for other patients with pericarditis without a record of pericardial effusion to investigate whether any increased risk of cancer depended on the presence of pericardial effusion. In the analysis with pericarditis as a potential prognostic factor, we constructed Kaplan-Meier survival curves to describe survival of cancer patients with and without a precancer pericarditis. We then used Cox proportional hazards regression to compare risks of death between the 2 cohorts at 3 months, 1 year, and 5 years after cancer diagnosis. We calculated hazard ratios (HRs) and associated 95% CIs, adjusting for sex, age, calendar year of diagnosis, and cancer type and stage (accounting for the matching by forming strata for the baseline hazard for the matched patients).
All codes are given in Appendix I in the online-only Data Supplement.
The study was approved by the Danish Data Protection Agency (record 1-16-02-1-08). Danish registry data are generally available to researchers, and in accordance with Danish law, use of this data does not require informed consent. All statistical analyses were conducted with SAS statistical software, version 9.4 (SAS Institute, Cary, NC).
RESULTS
Patient Characteristics
We identified 13 759 patients with pericarditis during a 20-year period, corresponding to an incidence rate of 168 cases per 100 000 individuals per year. Median age at pericarditis diagnosis was 49 years (interquartile range, 34-64 years), and 72% of the patients were male. Among the patients with pericarditis, 9758 (71%) had unclassified acute pericarditis, 1401 (10%) had acute infectious pericarditis, 2221 (16%) had pericardial effusion, and the remaining 379 (3%) had an autoimmune disease. Prevalent risk factors included recent thoracic surgery (11%), pneumonia/empyema (8%), myocardial infarction (6%), heart failure (6%), connective tissue disease (4%), implanted pacemaker (4%), tuberculosis (0.5%), and sepsis (1%; Table 1 ). The prevalence of chronic obstructive pulmonary disease and alcohol-related diagnoses was 4% each.
Most patients (79%) had pericarditis recorded as their primary discharge diagnosis. The remaining patients had the following conditions as the most frequent primary reason for their contact: other cardiovascular conditions (myocardial infarction, cardiac insufficiency, and atrial fibrillation), pneumonia, and empyema. There were differences in patients' characteristics according to type of hospital contact: Patients with emergency room diagnoses tended to be younger (median age, 34 years) and to have unclassified or infectious pericarditis. These patients also had a lower burden of underlying disease than patients with an inpatient or hospital outpatient diagnosis of pericarditis ( Figure I in the online-only Data Supplement).
Overall Cancer Risk
Overall, there were 1550 observed new cancer diagnoses among the patients with pericarditis versus 1070 expected during median follow-up of 6.4 years (interquartile range, 2.5-11.5 years), corresponding to an overall SIR of 1.5 (95% CI, 1.4-1.5).
ORIGINAL RESEARCH ARTICLE
Although all types of pericarditis were associated with an increased risk of subsequent cancer, patients with pericardial effusion had the highest incidence rate ratio (SIR=2.1; 95% CI, 1.9-2.3). For patients with unclassified pericarditis, the SIR was 1.3 (95% CI, 1.2-1.4); for patients with acute infectious pericarditis, the SIR was 1.3 (95% CI, 1.0-1.5); and for patients with underlying autoimmune disease, the SIR was 1.7 (95% CI, 1.2-2.3). The types of cancer underlying this increased cancer risk were cancers of the oral cavity, lung, heart, colon, kidney, prostate, and bladder, as well as lymphoma, leukemia, and unspecified metastatic cancer (Table 2) .
Cancer Risk During the First Year of Follow-Up
Within the first <3 months after an incident pericarditis diagnosis, 376 cancers were diagnosed among the 13 759 patients with pericarditis, corresponding to an absolute risk of 2.7%. More than half of the cases were lung cancers (n=210, 56%). Lymphoma accounted for 36 cases, leukemia for 16 cases, and unspecified metastatic cancers for 17 cases. The other cancer sites had ≤10 events each (Table 2) . Among cancers diagnosed during the same hospital contact as the qualifying pericarditis episode (n=123), lung cancer accounted for 52% (n=64) and non-Hodgkin lymphoma for 9% (n=11), and 7% (n=9) had unspecified metastatic cancer.
The 3-month SIR was 12.4 (95% CI, 11.2-13.7), driven mainly by lung cancer (SIR=65.0; 95% CI, 56.5-74.4). The risk of hematologic cancers also was markedly increased during the first 3 months of follow-up: 30-fold for non-Hodgkin lymphoma and up to 49-fold for myeloid leukemia ( Table 2 ). Other sites with excess cancer risks were the heart and thoracic cavity, pancreas, ovary, kidney, and bladder. However, the associated estimates were imprecise. The risk of breast cancer, albeit based on few cases, was increased 3-fold during this period.
During the 3 to <12 months after an incident pericarditis diagnosis, 123 cancers were registered, corresponding to a 1-year absolute cancer risk of 3.7% and an SIR of 1.5 (95% CI, 1.2-1.7; Table 2 ) for any cancer. The observed number of cases was greater than expected for lung and bladder cancer, non-Hodgkin lymphoma, and myeloid leukemia.
Cancer Risk ≥1 Years After Pericarditis
In ≥1 years after pericarditis, 1051 cancers were diagnosed compared with 954 expected. This corresponded to an SIR of 1.1 (95% CI, 1.0-1.2). Increased SIRs were observed for cancer of the oral cavity, colon, lung, and bladder and for non-Hodgkin lymphoma. In contrast, ≥1 years after a pericarditis diagnosis, no association was found between pericarditis and breast or unspecified metastatic cancers.
Subgroup Analysis by Patient Characteristics
Several patient characteristics modified the association between pericarditis and overall cancer risk. Both absolute and relative risks were higher in women than men. Absolute cancer risks rose with increasing age (Table 3) . However, relative risks were higher among patients <30 years of age than for older patients compared with the expected risk in the general population (as expected given the age-dependent increase in cancer risk; Figure 1) . P values for equality of the cumulative incidence functions were <0.0001 (ie, nonoverlapping CIs) in all strata (of sex, age groups, different pericarditis types, type of hospitalization, and diagnosis). We examined the SIRs for the different age groups and follow-up periods and found that all age groups had elevated 3-months SIRs, whereas only patients 50 to 69 years of age had elevated SIRs beyond 3 months of follow-up (Table I in the online-only Data Supplement).
In particular, patients with pericarditis with pericardial effusion had a high 3-month cancer risk (9.4%), followed by patients with pericarditis with autoimmune disease (4.5%). In contrast, patients with infectious pericarditis and unclassified pericarditis had cancer risks of 1.4% (Table 3) .
Although patients with an outpatient or inpatient diagnosis of pericarditis had almost the same increase in cancer risk (SIR=1.5), there was no evidence of an elevated cancer risk associated with pericarditis diagnosed only in the emergency room (SIR=1.0) (not presented in a table). Patients with a secondary pericarditis diagnosis had higher absolute cancer risks and a higher SIR than patients with pericarditis as their primary diagnosis (Table 3) .
Patients with pericarditis after recent thoracic surgery or recent myocardial infarction had a lower SIR for cancer than other patients with pericarditis ( Figure 1 ). Patients with chronic obstructive pulmonary disease, alcoholism-related diagnoses, or recent pneumonia had a higher SIR for cancer than patients without these diseases.
Characteristics and Cancer Risks in Patients With and Without Pericardial Effusion
We noted important differences within the groups of patients with pericarditis (Table II in the online-only Data Supplement). Compared with patients who did not have pericardial effusion, patients who had this complication were older (median age, 63 versus 46 years), had a shorter median follow-up time (4.0 versus 6.9 years), and were more likely to have their diagnosis entered in a secondary diagnosis field (34% versus 19%). The last difference was consistent with a greater prevalence of chronic and acute diseases and recent interventions. Specifically, patients with pericardial effusion had a higher prevalence than the remaining patients with pericarditis of heart failure (15% versus 4%), pacemak- ORIGINAL RESEARCH ARTICLE er implantation (10% versus 2%), chronic obstructive pulmonary disease (8% versus 3%), pneumonia or empyema (10% versus 7%), and recent thoracic surgery (42% versus 5%). Almost all patients (93%) with pericardial effusion had an echocardiography-confirmed diagnosis (Table II in the online-only Data Supplement).
Results from the supplemental analyses estimating SIRs for patients with pericarditis with and without pericardial effusion revealed higher cancer risks in patients with than in patients without pericardial effusion within the first year after diagnosis. The <3-month SIRs were 26-fold increased among patients with and 8-fold increased among those without pericardial effusion (Tables III and IV in the online-only Data Supplement). Cancer-specific SIRs were higher among patients with than among those without effusion for lung cancer, Hodgkin lymphoma, non-Hodgkin lymphoma, and unspecified metastatic cancer. Although the SIRs of breast and kidney cancers remained elevated among patients with pericardial effusion during the first <3 months, we found no association for these cancers among other patients with pericarditis during the first <3 months of follow-up (Tables III and IV in the online-only Data Supplement). In contrast, the SIRs for prostate and pancreas cancers were elevated among patients without pericardial effusion but not among patients with pericardial effusion (Tables III and IV in the online-only Data Supplement). During the 3-to <12-month followup period, patients with pericardial effusion continued to have higher-than-expected risks of lung cancer and non-Hodgkin lymphoma, whereas there was no convincing association for patients without pericardial effusion. In contrast, we found a persistently increased SIR for myeloid leukemia only among patients with pericarditis without pericardial effusion.
Beyond 1 year of follow-up, the SIRs of cancer for patients with pericarditis with and without pericardial effusion were overall in agreement with the main analysis. In particular, the risk of lung cancer remained elevated in patients both with and without pericardial effusion. Patients without pericardial effusion had an elevated SIR of cancers of the oral cavity, whereas no cases of this cancer type were observed among those with pericardial effusion. Only patients without pericardial effusion remained at an increased risk of colon cancer (Tables III  and IV in 
Pericarditis as a Prognostic Factor for Cancer Patients
The survival analyses included 1550 patients with pericarditis preceding their cancer diagnosis and a matched cohort of 7664 cancer patients without antecedent pericarditis. Reflecting successful matching, the median age was 67 years (interquartile range, 59-75 years), and 67% patients were male in both cohorts. Among the patients with pericarditis, 40% had localized cancer, 36% had metastatic cancer, and 24% had unknown or missing cancer stage. The corresponding proportions for patients without pericarditis were 42%, 37%, and 22%.
Regardless of the presence of pericarditis before a cancer diagnosis, cancer patients had poor outcomes (Figure 2 ). Three-month survival after any cancer was 80% for patients with and 86% for patients without pericarditis, corresponding to an adjusted HR of 1.5 (95% CI, 1.3-1.8) for cancer overall. For specific malignancies, the adjusted 3-month HR was 1.7 (95% CI, 1.4-2.0) for lung cancer, 2.0 (95% CI, 0.4-10.3) for breast cancer, and 0.8 (95% CI, 0.3-2.5) for non-Hodgkin lymphoma (Table 4 ). Survival at 1 year was 65% for patients with and 70% patients without pericarditis, and the 3-to 12-month HR was 1.3 (95% CI, 1.1-1.5).
Over time, pericarditis remained a prognostic factor for impaired cancer survival; after 5 years of follow-up, survival was 44% among cancer patients with previous pericarditis and 48% among patients without previous pericarditis (Figure 2 ). HRs 1 to <5 years after a cancer diagnosis preceded by pericarditis indicated persistent increased mortality for bladder cancer (HR=2.4; 95% CI, 1.3-4.2) and breast cancer (HR=2.2; 95% CI, 1.1-4.8; Table 4 ).
DISCUSSION
In this population-based nationwide cohort study, pericarditis was a marker for occult cancer. In particular, we observed a higher-than-expected rate of lung cancer, non-Hodgkin lymphoma, and myeloid leukemia during the first 3 months after an incident pericarditis diagnosis. Although the excess risk decreased for several cancers after the first 3 months, it nevertheless persisted for lung cancer, non-Hodgkin lymphoma, and bladder cancer diagnoses up to several years after a pericarditis diagnosis. We observed an increased cancer risk in both patients with and without pericardial effusion. No previous study has compared the prognostic impact of pericarditis preceding a cancer diagnosis. We found that pericarditis was a prognostic factor for both shortterm cancer survival after lung cancer and long-term cancer survival after bladder and breast cancer.
Primary tumors of the heart are rare, and the majority of cancer-related pericarditis cases are caused by P values for equality of the cumulative incidence functions were <0.0001 in all strata (within sex, within age groups, within different pericarditis types, within type of hospitalization and diagnosis). ORIGINAL RESEARCH ARTICLE metastatic tumors of remote origin. 29 The most common cancers with a known potential to spread to the pericardium include lung and breast cancer, lymphoma, and leukemia. 12 Other cancers leading to pericarditis through hematogenous spread include thymic, esophageal, bladder, kidney, and ovarian cancers. 7, 29 Moreover, pericarditis may occur as a part of the paraneoplastic syndrome. 13 In our unselected cohort of previously cancer-free patients, we corroborated some associations that earlier were described only as case reports [17] [18] [19] [20] or in small cohort studies (maximum of 453 patients) without comparison cohorts. 4, 6, 7 Most previous studies of pericarditis have sought to characterize its underlying causes and to examine prognostic factors for mortality. 4, 15, 30 The prognosis among patients with pericarditis is usually good, 31 but some characteristics are associated with a less favorable course. Coinfections (pneumonia and sepsis) and heart failure in patients with pericarditis increase inhospital mortality, 15 whereas fever >38°C, large effusions/tamponade, and nonsteroidal anti-inflammatory drug treatment failure are associated with poor 6-to 12-month survival. 4 Bacterial pericarditis, especially purulent pericarditis, is fatal if untreated, and mortality is high even in patients receiving proper treatment. 32 Among patients with known cancer, purulent pericarditis and pericardial effusion have serious implications for prognosis. 5, 33, 34 All Danish residents have tax-supported universal access to medical care, including hospital admission and treatment, which minimizes the risk of selection bias. Data in the Danish National Patient Registry are recorded by treating clinicians and registered mainly for administrative use. Because it is mandatory to report incident cancers to the DCR, we had complete cancer ascertainment (used both for exclusion of previous cancers and for cancer diagnosed during follow-up). The registry diagnoses included in our study generally are of high quality, 22, 23 and the positive predictive value of hospital-based pericarditis is 92% (95% CI, 85-96) overall and 97% (95% CI, 91-99) for inpatient diagnoses. 35 Because pericarditis is a serious disease, it is likely to lead to hospitalization, with diagnoses made mainly at highly specialized centers. Thus, the validity and completeness of our pericarditis definition are likely high.
However, our findings reflected outcome of pericarditis in patients with symptoms sufficiently severe to necessitate hospital referral by general practitioners or the prehospital emergency service and may differ from the outcome in patients with trivial symptoms of pericarditis.
Data on the incidence of pericarditis are sparse. One study reported an annual incidence of 30 per 100 000 individuals based on 274 patients diagnosed with pericarditis at 2 general hospitals (covering an urban area of 220 000 inhabitants). 2 In comparison, we included a nationwide cohort capturing individuals from the entire population of Denmark (≈7 million people alive between 1994 and 2013) diagnosed with pericarditis at both general hospitals and university hospitals. The difference may thus be explained by our populationbased setting.
A number of limitations must also be considered. There were some limitations in the clinical details available at the patient level in our register-based data. We had no information on the clinical presentation and therefore could not examine potential differences in cancer risk according to the clinical presentation.
Although the overall positive predictive value for pericarditis diagnosis is high, there may have been misclassification between the subtypes of pericarditis, potentially diluting differences in the associations of different subtypes with cancer.
We adjusted for age and sex by indirect standardization; we did not adjust for other factors. Although lifestyle factors are not strong risk factors for pericarditis, they may have modified the cancer risk. Unfortunately, we lacked data to sufficiently examine potential effect modification by smoking and alcohol use.
Patients with pericarditis as a secondary diagnosis had a higher risk of cancer than patients with pericarditis as the primary reason for their hospital contact. Pericarditis in a secondary position is indicative of additional or more severe morbidities at the time of the pericarditis diagnosis, which could explain the findings. Potentially, symptoms suggestive of cancer could have led to more thorough examination of these patients.
A few clinical factors may signal neoplastic origin of pericarditis, for example, unremitting course or recurrent episodes, pericardial effusion, or inefficient recovery after nonsteroidal anti-inflammatory drug treatment. 14 We confirmed that pericardial effusion is associated with high cancer risk; in fact, almost every 10th patient with pericardial effusion had a cancer diagnosis within the first 3 months after the pericarditis diagnosis.
We found especially high risks of lung cancer and non-Hodgkin lymphoma in patients with pericardial effusion, but we also found a higher short-term risk of lung cancer, breast cancer, non-Hodgkin lymphoma, and unspecific metastatic cancer. Patients without pericardial effusion had higher short-term risks of myeloid leukemia and prostate cancer and long-term risks of colon cancer and cancer of the oral cavity.
Patients with pericardial effusion were older and had higher prevalence of heart failure, pacemaker implantations, chronic obstructive pulmonary disease, and recent thoracic surgery than patients without pericardial effusion.
The overall stratified analyses showed that the presence of heart failure, chronic obstructive pulmonary disease, alcohol-related diagnoses, tuberculosis, and recent pneumonia or empyema was associated with elevated cancer SIRs among patients with pericarditis. Although these conditions are known to be associated with increased cancer risk, [36] [37] [38] they are not considered important confounders in the relationship between pericarditis and cancer. However, they could potentially be modifiers of the cancer risk among patients with pericarditis. Accordingly, patients with these conditions may have an increased risk of cancer and should thus be classified as high-risk patients. In contrast, patients with recent thoracic surgery or recent myocardial infarction had a lower SIR than patients without this history. This finding accords with a lower a priori cancer risk among patients with underlying diseases not strongly related to cancer. However, the lower SIR for patients who underwent thoracic surgery may also indicate that patients with obvious signs of cancer were deemed unsuitable for surgery.
In agreement with the previous guidelines for diagnostic workup in patients with pericarditis, the workup conducted in patients in our cohort may have been targeted mainly at excluding myocardial infarction (ie, ECG, echocardiography, examination of biomarkers for acute cardiac ischemia, chest x-ray). However, the updated guidelines recommend additional assessment of markers of inflammation (ie, C-reactive protein or erythrocyte sedimentation rate), white blood cell count with differential count, renal function, liver tests, and tests indicating myocardial lesion (creatine kinase and troponin) in all cases of suspected pericarditis. 1 In addition, further testing (eg, computed tomography scan) is indicated in high-risk patients according to clinical indicators (fever >38°C, subacute course, large pericardial effusion, cardiac tamponade, or failure of aspirin or nonsteroidal anti-inflammatory drugs). 1 The clinical value of the different diagnostic tests was summarized in a review showing that malignancy as a cause shares several features with other causes. 8 Clinical examination with auscultation, ECG, echocardiography, and markers of inflammation does not discriminate between causes, whereas more specific tumor makers and computed tomography or cardiac magnetic resonance could lead to diagnosis. 8 In a study examining 55 patients with effusion, computed tomography revealed pathological findings in all patients with malignancy, whereas clinical and biochemical data were not able to differentiate between malignant and nonmalignant causes. 39 The final diagnosis of neoplastic pericarditis requires isolation of neoplastic cells from pericardial fluid by pericardiocentesis and histological examination of pericardial biopsies. 5 The frequent use of x-ray or other imaging examinations in our cohort could have revealed lung cancer or lymphoma or led to a more thorough investigation that identified cancers that may or may not have been related to pericarditis. Accordingly, our results for the initial 3-month follow-up period are likely influenced by heightened diagnostic effort to some degree. We observed an increased risk of most cancers during that period but no clear compensatory drop in incidence ratios in the later follow-up period. Without access to patients' medical records, it is difficult to differentiate patients whose pericarditis was the first manifestation of advanced cancer from those whose pericarditis occurred coincidentally with cancer. In contrast, cancers diagnosed >1 year after a pericarditis diagnosis are unlikely to be subject to detection bias, although some may have been present at the time of pericarditis diagnosis.
Clinically, it is important to know whether patients presenting with first-time pericarditis should be investigated more thoroughly to rule out specific cancers. An x-ray examination potentially could lead to detection of lung cancer, metastatic cancer, or lymphoma. We speculate that if the standard workup in our cohort of patients had included tests such as a complete blood count, liver enzyme level, and computed tomography scan, then additional cancers might have been detected earlier. Patients both with and without effusion had elevated relative risks of several cancers, but the absolute risks were low. Accordingly, the number needed to examine to detect additional cancers would be high. Thus, economic and patient-related costs, including exposure to radiation and anxiety associated with the diagnostic workup, may outweigh the clinical utility of an extended screening such as whole-body scans. Nevertheless, our results may raise awareness for lung cancer and non-Hodgkin lymphoma in patients presenting with pericardial effusion.
CONCLUSIONS
Pericarditis may be a marker of occult lung and breast cancer, as well as hematologic and unspecified metastatic cancers. The increased diagnosis rate of cancers of the heart and thoracic cavity, pancreas, kidney, and bladder may represent metastatic spread of such cancers to the pericardium. Although cancer risk was increased in patients both with and without pericardial effusion, pericardial effusion was associated with particular high cancer incidence, specifically lung cancer, lymphoma, and unspecified metastatic cancer. Although pericarditis is associated with a worse survival among patients with certain cancers, it is unclear whether earlier detection of cancer improves survival.
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